$110M Boost Fuels Bridge to Life’s Push for Standardized Liver Transplant Perfusion
Event summary
- $110M Series C and debt financing led by Soleus Capital and Lauxera Capital Partners.
- VitaSmart™ HOPE System gained FDA De Novo clearance in January 2026 for liver transplantation.
- Funds to expand commercial reach, develop organ viability assessment tool, and broaden product pipeline beyond liver transplants.
The big picture
Bridge to Life’s $110M raise underscores investor confidence in its ability to standardize hypothermic oxygenated perfusion in liver transplantation. The funding comes as the company transitions from a developmental stage to full commercialization, with plans to expand into other solid organ transplants. This strategic shift positions Bridge to Life to capitalize on the critical need for improved organ preservation technologies amid a growing transplant waitlist.
What we're watching
- Market Adoption Pace
- How quickly VitaSmart™ can achieve widespread adoption across U.S. transplant centers.
- Pipeline Execution
- Whether Bridge to Life can successfully expand its product portfolio beyond liver transplantation within the next three years.
- Regulatory Clearance
- The timeline for FDA clearance of the proprietary viability assessment tool currently in development.
Related topics